Elena Geuna

Research output

Research output per year 2011 2015 2016 2020 2022

• 28 Article
• 5 Review article
• 1 Editorial

Research output per year

Research output per year

Search results

• 2022

  Circulating Cytokines in Metastatic Breast Cancer Patients Select Different Prognostic Groups and Patients Who Might Benefit from Treatment beyond Progression

  Paccagnella, M., Abbona, A., Michelotti, A., Geuna, E., Ruatta, F., Landucci, E., Denaro, N., Vanella, P., Lo Nigro, C., Galizia, D., Merlano, M. & Garrone, O., Jan 2022, In: Vaccines. 10, 1, 78.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Molecular Cluster 100%
  • Breast Neoplasms 98%
  • Cytokines 95%
  • Interleukin-8 63%
  • Interleukin-10 58%
• 2021

  Cancer of unknown primary stem-like cells model multi-organ metastasis and unveil liability to MEK inhibition

  Verginelli, F., Pisacane, A., Gambardella, G., D'Ambrosio, A., Candiello, E., Ferrio, M., Panero, M., Casorzo, L., Benvenuti, S., Cascardi, E., Senetta, R., Geuna, E., Ballabio, A., Montemurro, F., Sapino, A., Comoglio, P. M. & Boccaccio, C., May 3 2021, In: Nat. Commun.. 12, 1, p. 2498

  Research output: Contribution to journal › Article › peer-review

  • Mitogen-Activated Protein Kinase Kinases 100%
  • Stem Cells 67%
  • Neoplasm Metastasis 56%
  • Neoplasms 29%
  • Genetic Background 16%
• 2020

  Cancer of Unknown Primary (CUP): genetic evidence for a novel nosological entity? A case report

  Benvenuti, S., Milan, M., Geuna, E., Pisacane, A., Senetta, R., Gambardella, G., Stella, G. M., Montemurro, F., Sapino, A., Boccaccio, C. & Comoglio, P. M., Jan 1 2020, (Accepted/In press) In: EMBO Molecular Medicine.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Neoplasm Metastasis 100%
  • Neoplasms 60%
  • Mutation 45%
  • Exome 32%
  • Autopsy 22%

• Cancer of Unknown Primary (CUP): genetic evidence for a novel nosological entity? A case report

  Benvenuti, S., Milan, M., Geuna, E., Pisacane, A., Senetta, R., Gambardella, G., Stella, G. M., Montemurro, F., Sapino, A., Boccaccio, C. & Comoglio, P. M., Jul 7 2020, In: EMBO Molecular Medicine. 12, 7, p. e11756

  Research output: Contribution to journal › Article › peer-review

  • Neoplasm Metastasis 100%
  • Neoplasms 60%
  • Mutation 45%
  • Exome 32%
  • Autopsy 22%

• Exploratory analysis of circulating cytokines in patients with metastatic breast cancer treated with eribulin: the TRANSERI-GONO (Gruppo Oncologico del Nord Ovest) study

  Garrone, O., Michelotti, A., Paccagnella, M., Montemurro, F., Vandone, A. M., Abbona, A., Geuna, E., Vanella, P., De Angelis, C., Lo Nigro, C., Falletta, A., Crosetto, N., Di Maio, M. & Merlano, M., Oct 2020, In: ESMO Open. 5, 5, p. e000876

  Research output: Contribution to journal › Article › peer-review

  • eribulin 100%
  • Transforming Growth Factors 55%
  • interleukin-21 41%
  • Breast Neoplasms 38%
  • Cytokines 37%

• MiR-100 is a predictor of endocrine responsiveness and prognosis in patients with operable luminal breast cancer

  Petrelli, A., Bellomo, S. E., Sarotto, I., Kubatzki, F., Sgandurra, P., Maggiorotto, F., Di Virgilio, M. R., Ponzone, R., Geuna, E., Galizia, D., Nuzzo, A. M., Medico, E., Miglio, U., Berrino, E., Venesio, T., Ribisi, S., Provero, P., Sapino, A., Giordano, S. & Montemurro, F., Oct 2020, In: ESMO Open. 5, 5, p. e000937

  Research output: Contribution to journal › Article › peer-review

  • Breast Neoplasms 100%
  • Datasets 30%
  • Biomarkers 25%
  • Prospective Studies 24%
  • human ERBB2 protein 24%

• Treatment with Beta-Blockers and ACE-Inhibitors in Breast Cancer Patients Receiving Adjuvant Trastuzumab-Based Therapy and Developing Mild Cardiac Toxicity: A Prospective Study

  Geuna, E., Lombardi, P., Martinello, R., Garino, D., Bonzano, A., Galizia, D., Nuzzo, A., Berchialla, P., Becco, P., Mangioni, M., Zarlo, L. D. & Montemurro, F., Jan 31 2020, In: Cancers. 12, 2

  Research output: Contribution to journal › Article › peer-review

  • Trastuzumab 100%
  • Cardiotoxicity 95%
  • Angiotensin-Converting Enzyme Inhibitors 83%
  • Breast Neoplasms 53%
  • Prospective Studies 53%
• 2018

  Self-evaluation of duration of adjuvant chemotherapy side effects in breast cancer patients: A prospective study

  Galizia, D., Milani, A., Geuna, E., Martinello, R., Cagnazzo, C., Foresto, M., Longo, V., Berchialla, P., Solinas, G., Calori, A., Grasso, B., Volpone, C., Bertola, G., Parola, G., Tealdi, G., Giuliano, P. L., Ballari, A. M., Aglietta, M. & Montemurro, F., Sep 1 2018, In: Cancer Medicine. 7, 9, p. 4339-4344 6 p.

  Research output: Contribution to journal › Article › peer-review

  • Diagnostic Self Evaluation 100%
  • Adjuvant Chemotherapy 84%
  • Breast Neoplasms 53%
  • Prospective Studies 53%
  • Terminology 31%

• What is the best pharmacotherapeutic strategy for HER-2 positive breast cancer?

  Giannone, G., Milani, A., Geuna, E., Galizia, D., Biello, F. & Montemurro, F., Nov 6 2018, (E-pub ahead of print) In: Expert Opinion on Pharmacotherapy. p. 1-5 5 p.

  Research output: Contribution to journal › Article › peer-review
• 2017

  A first-in-human, Phase I, dose-escalation study of TAK-117, A selective PI3Ka isoform inhibitor, in patients with advanced solid malignancies

  Juric, D., De Bono, J. S., LoRusso, P. M., Nemunaitis, J., Heath, E. I., Kwak, E. L., Mercade, T. M., Geuna, E., De Miguel-Luken, M. J., Patel, C., Kuida, K., Sankoh, S., Westin, E. H., Zohren, F., Shou, Y. & Tabernero, J., Sep 1 2017, In: Clinical Cancer Research. 23, 17, p. 5015-5023 9 p.

  Research output: Contribution to journal › Article › peer-review

  • serabelisib 100%
  • Protein Isoforms 34%
  • Neoplasms 13%
  • 5-(aminomethyl)-6-(2,2-dimethylpropyl)-2-ethyl-4-(4-methylphenyl)pyridin-3-ylacetic acid 12%
  • Safety 6%

• Genotyping tumour DNA in cerebrospinal fluid and plasma of a HER2-positive breast cancer patient with brain metastases.

  Siravegna, G., Geuna, E., Mussolin, B., Crisafulli, G., Bartolini, A., Galizia, D., Casorzo, L., Sarotto, I., Scaltriti, M., Sapino, A., Bardelli, A. & Montemurro, F., 2017, In: ESMO Open. 2, p. e000253

  Research output: Contribution to journal › Article › peer-review

  • Circulating Tumor DNA 100%
  • human ERBB2 protein 85%
  • Cerebrospinal Fluid 60%
  • Breast Neoplasms 44%
  • Neoplasm Metastasis 42%
• 2016

  Investigational ErbB-2 tyrosine kinase inhibitors for the treatment of breast cancer

  Martinello, R., Milani, A., Geuna, E., Zucchini, G., Aversa, C., Nuzzo, A. & Montemurro, F., Apr 2 2016, In: Expert Opinion on Investigational Drugs. 25, 4, p. 393-403 11 p.

  Research output: Contribution to journal › Article › peer-review

  • TYK2 Kinase 100%
  • Breast Neoplasms 41%
  • Investigational Drugs 30%
  • Trastuzumab 25%
  • Gene Amplification 25%
• 2015

  Adjuvant ovarian suppression in premenopausal breast cancer

  Montemurro, F., Perrone, F. & Geuna, E., Apr 23 2015, In: New England Journal of Medicine. 372, 17, p. 1672-1673 2 p.

  Research output: Contribution to journal › Article › peer-review

• Adjuvant ovarian suppression in premenopausal breast cancer

  Montemurro, F., Perrone, F. & Geuna, E., Apr 23 2015, In: New England Journal of Medicine. 372, 17, p. 1672-1673 2 p.

  Research output: Contribution to journal › Article › peer-review

• Buparlisib, an oral pan-PI3K inhibitor for the treatment of breast cancer

  Geuna, E., Milani, A., Martinello, R., Aversa, C., Valabrega, G., Scaltriti, M. & Montemurro, F., 2015, In: Expert Opinion on Investigational Drugs. 24, 3, p. 421-431 11 p.

  Research output: Contribution to journal › Article › peer-review

  • NVP-BKM120 100%
  • Phosphatidylinositol 3-Kinase 57%
  • Breast Neoplasms 36%
  • TOR Serine-Threonine Kinases 25%
  • Class I Phosphatidylinositol 3-Kinases 21%

• Clinical utility of exemestane in the treatment of breast cancer

  Zucchini, G., Geuna, E., Milani, A., Aversa, C., Martinello, R. & Montemurro, F., May 27 2015, In: International Journal of Women's Health. 7, p. 551-563 13 p.

  Research output: Contribution to journal › Article › peer-review

  • exemestane 100%
  • Breast Neoplasms 42%
  • Aromatase Inhibitors 29%
  • Estrogen Receptor Modulators 15%
  • Tamoxifen 12%

• Complications of hyperglycaemia with PI3K-AKT-mTOR inhibitors in patients with advanced solid tumours on Phase I clinical trials

  Geuna, E., Roda, D., Rafii, S., Jimenez, B., Capelan, M., Rihawi, K., Montemurro, F., Yap, T. A., Kaye, S. B., De Bono, J. S., Molife, L. R. & Banerji, U., Dec 1 2015, In: British Journal of Cancer. 113, 11, p. 1541-1547 7 p.

  Research output: Contribution to journal › Article › peer-review

  • Clinical Trials, Phase I 100%
  • Phosphatidylinositol 3-Kinases 81%
  • Hyperglycemia 75%
  • Neoplasms 26%
  • Incidence 24%

• Higher risk of infections with PI3K-AKT-mTOR pathway inhibitors in patients with advanced solid tumors on phase I clinical trials

  Rafii, S., Roda, D., Geuna, E., Jimenez, B., Rihawi, K., Capelan, M., Yap, T. A., Molife, L. R., Kaye, S. B., De Bono, J. S. & Banerji, U., Apr 15 2015, In: Clinical Cancer Research. 21, 8, p. 1869-1876 8 p.

  Research output: Contribution to journal › Article › peer-review

  • Clinical Trials, Phase I 100%
  • Phosphatidylinositol 3-Kinases 81%
  • Infections 39%
  • Neoplasms 26%
  • Confidence Intervals 16%

• Linifanib: Current status and future potential in cancer therapy

  Aversa, C., Leone, F., Zucchini, G., Serini, G., Geuna, E., Milani, A., Valdembri, D., Martinello, R. & Montemurro, F., Jun 1 2015, In: Expert Review of Anticancer Therapy. 15, 6, p. 677-687 11 p.

  Research output: Contribution to journal › Article › peer-review

  • N-(4-(3-amino-1H-indazol-4-yl)phenyl)-N1-(2-fluoro-5-methylphenyl)urea 100%
  • Neoplasms 16%
  • Clinical Trials 13%
  • Angiogenesis Inducing Agents 11%
  • Protein-Tyrosine Kinases 9%

• The neutrophil-lymphocyte ratio and its utilisation for the management of cancer patients in early clinical trials

  Kumar, R., Geuna, E., Michalarea, V., Guardascione, M., Naumann, U., Lorente, D., Kaye, S. B. & De Bono, J. S., Mar 31 2015, In: British Journal of Cancer. 112, 7, p. 1157-1165 9 p.

  Research output: Contribution to journal › Article › peer-review

  • Neutrophils 100%
  • Lymphocytes 88%
  • Clinical Trials 83%
  • Neoplasms 41%
  • Clinical Trials, Phase I 22%
• 2014

  FDG avidity at PET/CT during adjuvant hormonal therapy in patients with breast cancer

  Evangelista, L., Redana, S., Racca, M., Geuna, E., Vinante, L., Zago, G., De Carolis, V., Ghiotto, C., Saladini, G. & Varetto, T., Feb 2014, In: Clinical Nuclear Medicine. 39, 2

  Research output: Contribution to journal › Article › peer-review

  • Breast Neoplasms 100%
  • Tumor Biomarkers 76%
  • Chi-Square Distribution 75%
  • Hormones 55%
  • Students 54%

• Metastatic breast cancer subtypes and central nervous system metastases

  Aversa, C., Rossi, V., Geuna, E., Martinello, R., Milani, A., Redana, S., Valabrega, G., Aglietta, M. & Montemurro, F., Oct 1 2014, In: Breast. 23, 5, p. 623-628 6 p.

  Research output: Contribution to journal › Article › peer-review

  • Central Nervous System 100%
  • Breast Neoplasms 86%
  • Neoplasm Metastasis 83%
  • Survival 24%
  • Phenobarbital 24%

• Overcoming endocrine resistance in metastatic breast cancer: Current evidence and future directions

  Milani, A., Geuna, E., Mittica, G. & Valabrega, G., Dec 10 2014, In: World Journal of Clinical Oncology. 5, 5, p. 990-1001 12 p.

  Research output: Contribution to journal › Article › peer-review

  • Direction compound 100%
  • Breast Neoplasms 88%
  • Estrogen Receptors 64%
  • exemestane 51%
  • Anastrozole 49%
• 2012

  Current status and future perspectives in the endocrine treatment of postmenopausal, hormone receptor-positive metastatic breast cancer

  Montemurro, F., Rossi, V., Geuna, E., Valabrega, G., Martinello, R., Milani, A. & Aglietta, M., Oct 2012, In: Expert Opinion on Pharmacotherapy. 13, 15, p. 2143-2156 14 p.

  Research output: Contribution to journal › Article › peer-review

  • Hormones 100%
  • Breast Neoplasms 90%
  • Medical Oncology 41%
  • Therapeutics 23%
  • Expert Testimony 18%

• Potential of afatinib in the treatment of patients with HER2-positive breast cancer

  Geuna, E., Montemurro, F., Aglietta, M. & Valabrega, G., Aug 24 2012, In: Breast Cancer: Targets and Therapy. 4, p. 131-137 7 p.

  Research output: Contribution to journal › Article › peer-review

  • Afatinib 100%
  • human ERBB2 protein 80%
  • Breast Neoplasms 41%
  • Protein-Tyrosine Kinases 19%
  • Clinical Trials, Phase I 13%
• 2011

  Hitting multiple targets in HER2-positive breast cancer: Proof of principle or therapeutic opportunity?

  Geuna, E., Milani, A., Redana, S., Rossi, V., Valabrega, G., Aglietta, M. & Montemurro, F., Mar 2011, In: Expert Opinion on Pharmacotherapy. 12, 4, p. 549-565 17 p.

  Research output: Contribution to journal › Article › peer-review

  • Breast Neoplasms 100%
  • Trastuzumab 74%
  • Receptor Protein-Tyrosine Kinases 33%
  • Biological Factors 33%
  • Expert Testimony 32%

• Trastuzumab beyond progression in retrospective analyses: An issue of equal opportunities

  Montemurro, F., Redana, S., Geuna, E., Milani, A., Rossi, V., Martinello, R., Valabrega, G. & Aglietta, M., 2011, In: The oncologist. 16, 4, p. 534-536 3 p.

  Research output: Contribution to journal › Article › peer-review

• Trastuzumab in the adjuvant setting: A practical review

  Rossi, V., Redana, S., Milani, A., Geuna, E., Valabrega, G., Aglietta, M. & Montemurro, F., Mar 2011, In: Therapy. 8, 2, p. 161-177 17 p.

  Research output: Contribution to journal › Article › peer-review

  • Trastuzumab 100%
  • Breast Neoplasms 23%
  • Drug Therapy 22%
  • Anthracyclines 10%
  • Adjuvant Chemotherapy 9%